Bayer ’s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study (for specialized target groups only)

Study with more than 3,000 patients investigated rivaroxaban 10 mg and 20 mg once daily versus aspirin 100 mg once daily / Both rivaroxaban treatment arms were superior in preventing recurrent venous thromboembolism while showing comparable and very low rates of major bleeding versus aspirin / Risk of recurrent thrombosis is up to 10% in the first year if anticoagulation therapy is stopped / Data were presented in a late-breaking clinical trial session at ACC.17 and published simultaneously in The New England Journal of Medicine
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news